NetworkNewsBreaks – Willow Biosciences Inc. (TSX
Post# of 23
(Total Views: 125)
Posted On: 09/21/2020 3:30:08 PM
NetworkNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Achieves Scalable Production of Pure CBG
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced that it has successfully developed a scalable process, with demonstrated production at 500 litre scale, for producing cannabigerol (“CBG”) with greater than 99% purity and no detectable tetrahydrocannabinol (“THC”). “Achieving scalable production of pure CBG is a pivotal milestone for both Willow and our industry” said Willow’s Chief Executive Officer Trevor Peters in the press release. “The market opportunity for high-purity cannabinoids manufactured under GMP control is expected to be in the billions of dollars in the coming years, and as the first company to successfully produce product samples, Willow is poised to capture a sizable portion of that market. We anticipate being able to begin commercialization of CBG in the first half of 2021 and are currently selecting manufacturing partners to assist us in reaching both local and worldwide markets.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, today announced that it has successfully developed a scalable process, with demonstrated production at 500 litre scale, for producing cannabigerol (“CBG”) with greater than 99% purity and no detectable tetrahydrocannabinol (“THC”). “Achieving scalable production of pure CBG is a pivotal milestone for both Willow and our industry” said Willow’s Chief Executive Officer Trevor Peters in the press release. “The market opportunity for high-purity cannabinoids manufactured under GMP control is expected to be in the billions of dollars in the coming years, and as the first company to successfully produce product samples, Willow is poised to capture a sizable portion of that market. We anticipate being able to begin commercialization of CBG in the first half of 2021 and are currently selecting manufacturing partners to assist us in reaching both local and worldwide markets.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)